Shares of Pfenex (NYSE: PFNX) jumped over 15% in today's pre-market trading session as the clinical-stage biotech company received approval from the
Categories
Health Care
Two zero-revenue biotech stocks debut in a shaky IPO market
The IPO market has recently been pretty unwelcoming, with some of the popular firms going dud right after their debut. Endeavor Group
Strong pipeline and innovation make Novartis a sure bet, despite setbacks
The uncertainties surrounding drug development and intense competition are the primary challenges facing pharmaceutical companies, which also prompt investors to approach the
Rite Aid swings to profit in Q2, stock gains strength
Pharmacy retailer Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of 2020, from a loss in the year-over
Ovid Therapeutics stock gains on positive epilepsy trial data
Ovid Therapeutics Inc. (NASDAQ: OVID) stock climbed to an 8-month high of $3.05 on Tuesday after positive initial data from rare epilepsies
Wall St expecting a turn-around quarter from Rite Aid in Q2
Things haven’t been working out so well for Rite Aid (NYSE: RAD) since the past three years. The company’s inability to stop
Will Zynerba Zygel trial be extended amid safety warning?
Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel.
Three companies that are haunted by multiple lawsuits
Several companies have battled lawsuits from time to time for various reasons. However, sometimes companies face thousands of lawsuits for one reason.
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be the takeover
Lundbeck to acquire Alder BioPharmaceuticals for $1.95 billion; Alder stock hits new 52-week high
Denmark-based biopharma company Lundbeck announced today that it will acquire Alder BioPharmaceuticals (NASDAQ: ALDR) for $1.95 billion. Alder stock, which reached a
Will Allergan-AbbVie merger be intercepted
Allergan plc (NYSE: AGN) continued to dominate in the tissue expander market as the demand for plastic surgeries is increasing from the
SmileDirectClub goes public; opens 11% below its IPO price of $23
Dentistry company SmileDirectClub (NASDAQ: SDC) opened at $20.55, down 11% from its IPO price of $23 on its debut day. The five-year
Catalyst Pharmaceuticals stock soars to record high
Catalyst Pharmaceuticals (NASDAQ: CPRX) stock soared to a record high of $7.67 on Wednesday as phase 3 trial results date is nearing
Earnings preview: Market has low expectations ahead of Advaxis’ Q3 report
Advaxis (NASDAQ: ADXS), a late-stage biotech firm, is one of the worst-performing healthcare stocks that continuously disappointed investors over the years. Though
Novartis scores another point in multiple sclerosis therapy, stock rises
Swiss pharmaceutical giant Novartis International AG (NYSE: NVS) on Friday said its ofatumumab met the primary and secondary endpoints of Phase 3
Johnson & Johnson tumbles on rating downgrade, after opioid ruling
Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as investor mood
4 biotech stocks that are ideal takeover targets
Speculation plays a big role when investing in biotech stocks, hence making them highly volatile. It could be after years of stock
Lannett stock jumps more than 15% after topping Q4 earnings and revenue estimates
Generic drug manufacturer Lannett's (NYSE: LCI) stock surged more than 15% after it reported Q4 earnings results. The company's bottom line and
Veeva Systems Q2 profit beats estimates, CFO Tim Cabral to retire
Veeva Systems Inc. (NYSE: VEEV) reported a 58% jump in earnings for the second quarter of 2020 as higher subscription services revenue
Why Arbutus Biopharma stock dipped to 11-year low?
Arbutus Biopharma Corporation (NASDAQ: ABUS) stock plunged to an 11-year low of $1.31 on Monday due to considerable downside risk and unsatisfactory
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.